Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

July 5, 2001

Primary Completion Date

December 31, 2004

Conditions
Leukemia
Interventions
BIOLOGICAL

alemtuzumab

BIOLOGICAL

filgrastim

DRUG

cyclophosphamide

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Trial Locations (14)

15236

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

19104

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

54449

CCOP - Marshfield Clinic Research Foundation, Marshfield

55416

CCOP - Metro-Minnesota, Saint Louis Park

60611

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

60611-4494

Veterans Affairs Medical Center - Lakeside Chicago, Chicago

02111

Cancer Center at Tufts - New England Medical Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

07601

CCOP - Northern New Jersey, Hackensack

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

17033-0850

Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey

19111-2497

Fox Chase Cancer Center, Philadelphia

53792-0001

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT00006390 - Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter